Note that some links may require registration or subscription.
Moderna announced that its phase III TeenCOVE trial met the primary endpoint, with its COVID vaccine in kids ages 12 to 17 demonstrating non-inferior immunogenicity versus an adult comparator group, and showing 93-100% efficacy after the second dose.
Describing the "scandalous inequity" in global COVID-19 vaccine distribution, WHO Director-General Tedros Adhanom Ghebreyesus, PhD, called on wealthier countries to donate enough supply so that 30% of every nation could be inoculated by year's end. (
Reuters)
Pfizer has begun testing its pneumonia vaccine along with a third shot of its COVID vaccine in people over 65, to see if the vaccine combination is safe and what immune response it induces. (